Core Insights - New analyses from the Phase 2b RewinD-LB clinical trial indicate that DLB patients with lower plasma pTau181 levels experienced greater clinical benefits from neflamapimod, suggesting its potential to target the underlying causes of dementia with Lewy bodies (DLB) [1][2][12] - The findings support the company's patient enrichment strategy and dosing regimen for the upcoming Phase 3 trial [1][2] Clinical Trial Details - The RewinD-LB trial included an initial randomized phase comparing neflamapimod to placebo, followed by a neflamapimod-only extension phase [3][8] - In the initial phase, participants did not achieve expected plasma drug concentration levels, resulting in no statistically significant improvement on the primary endpoint [3][4] - The extension phase with a new batch of capsules (DP Batch B) showed statistically significant and clinically meaningful slowing of disease progression [4] Treatment Response and Biomarkers - Treatment response increased across DLB patient subgroups with lower pTau181 levels, indicating a higher likelihood of patients without Alzheimer's disease (AD) co-pathology benefiting from neflamapimod [2][5] - The analyses revealed a consistent improvement in clinical endpoints at progressively lower plasma pTau181 levels, with a significant difference in CDR-SB scores between treatment groups [5][6] Future Directions - The company plans to initiate a global Phase 3 trial in the second half of 2026, focusing on patients with DLB and low pTau181 levels [14] - The planned trial will utilize a pTau181 cut-off of <21 pg/mL, estimated to include 80-90% of patients without AD co-pathology, who are believed to be most likely to respond to treatment [6][12] Drug Mechanism and Efficacy - Neflamapimod is an investigational drug that inhibits p38 MAP kinase, targeting neuroinflammation and synaptic dysfunction [12][13] - Previous studies have shown that neflamapimod can restore synaptic function and improve cognitive and functional outcomes in DLB patients [13]